搜索历史清除全部记录
- All
- Product Management
- News
- Introduction
- Enterprise outlets
- FAQ
- Enterprise Video
- Enterprise Atlas
About Us
Zhejiang Angel Biopharm Co., Ltd.
On January 20, 2022, Zhejiang Angel Biopharm Co., Ltd. was established in Xianju, Taizhou, Zhejiang. The company is located in the scenic Xianju Yangfu Industrial Zone; it is a joint venture company led by integrating industry resources and professional technical teams; mainly positioning high-end biomedical products and high-end sterile raw materials and other products R & D, production and sales.
The main members of the company's management team are from pharmaceutical companies, with an average of more than 15 years of industry experience and an average age of less than 40 years. Experienced and dynamic management team is the basis for the company's standardized management and long-term development. The company insists on relying on scientific and technological innovation, taking the road of sustainable development, taking non-steroidal high-end sterile raw materials and biomedicine as the company's development direction, integrating product research, development, production, processing and sales, and establishing a complete product system, Strive to become a compound high-tech industrial company covering many fields such as medicine, beauty, food and cosmetics.
The company's main products are sodium hyaluronate, which is used to cover food, cosmetics, medical devices and pharmaceutical products. The company is committed to using its own unique technology to produce high quality products, pay more attention to the production of high-end sterile hyaluronic acid. In addition to its own R & D products, the company has close cooperation with university research institutes and R & D companies. In the future, the company will pay more attention to products in biomedicine, new drug synthesis processes and sterile APIs.
The company is currently under construction and will have a production capacity of more than 200 tons upon completion. At the same time, the company has already started the construction of the enterprise's drug quality management system and the drug registration of its products. It is expected to complete the product registration of China NMPA, US FDA and European EDQM and pass the relevant GMP certification in 2026.
As a new type of biomedical manufacturing company, we firmly believe that professionalism and hard work can bring greater value. To become an international high-quality pharmaceutical company is our vision, adhering to the open learning, sharing and cooperative working attitude, and strive to become an angel of human health care.
Culture
Open
Focus
Innovation
Cooperation
Honor
